Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
37m
on MSN
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
19h
Jeff Smith, the activist picking a fight with Covid hero Pfizer
Then $75 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.
BioSpace
20h
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Grateful Dead bassist dies
DOJ reaches settlement
Sentenced for Jan. 6 role
DNA tests identify skull
NASA astronaut hospitalized
Dismissal of charge upheld
Arlington incident report
Jeffries pleads not guilty
Apology for past US policy
Israel strikes back at Iran
Murder-for-hire plot arrest
Recalls chicken products
CO ballots to be reexamined
Madigan corruption trial
SC teen voting glitch
World's most valuable firm
E. coli infections rise to 75
Gaza peace talks to resume?
VA voter roll purge blocked
Won't endorse candidates
Phones hacked by China?
PA registration fraud probe
Louisiana forces relocation
Approves Iterum's treatment
MS late ballots count ruling
Exonerated after 22 years
Browns sue city of Cleveland
ABC News icon Jarriel dies
Announces layoffs, jet sales
New student loan relief plan
Feedback